規劃投資30億元布局鈉電量產！中比新能源與南京高淳經濟開發區簽署12GWh鈉電產能投資協議

CBAK Energy (NASDAQ: CBAT) signed an investment agreement for a planned 12GWh sodium-ion cell and integrated battery-system project in Nanjing Gaochun, involving approximately RMB3.0 billion of investment. At full utilization, the project is projected to add RMB4.8-5.0 billion in annual revenue, with construction-related work targeted to begin in H2 2027, subject to financing and approvals. The lithium/sodium shared production lines are intended to lower capital and operating risk while supporting commercialization of sodium-ion cells for energy storage, light electric vehicles and specialty power applications; however, revenue estimates are not contracted sales or formal guidance.

Analysis

CBAT's valuation response should be governed by financing credibility rather than the headline capacity figure. The projected revenue implies roughly RMB0.40-0.42/Wh, a realization level that may be difficult to sustain in low-end stationary storage and light-mobility markets as lithium iron phosphate (LFP) pricing remains depressed. Because construction does not begin until 2H27 and the project is explicitly financing-dependent, this is not near-term earnings visibility; it is a future capital-intensity and dilution question for a micro-cap issuer.

The dual-chemistry line has option value, but only if conversion costs, yields, and certification cycles are demonstrably comparable with dedicated lithium lines. The more likely early market for sodium-ion is cold-weather backup power, telecom/industrial storage, and low-speed mobility—not EV traction—where energy-density penalties are tolerable and safety/cycle-life matter. That creates competitive pressure primarily on lead-acid suppliers and lower-tier LFP cell makers, while CATL (300750.SZ) and BYD (1211.HK) retain scale, customer qualification, and balance-sheet advantages that limit CBAT's ability to earn premium margins.

Near term, a press-release-driven CBAT spike is vulnerable to liquidity-driven reversal absent disclosed capex, financing source, customer offtake, or third-party product qualification. Over 1-3 months, the relevant catalysts are binding equipment orders, local-government incentives, and named customer validation; over 6-18 months, watch whether the existing expansion reaches utilization and generates operating cash flow before additional commitments. The contrarian view is that flexible capacity is an inexpensive hedge against sodium adoption, but the market should assign little value until management proves that flexibility does not mask underutilized lithium capacity.

Thesis falsification is a funded project structure with limited equity issuance, contracted offtake covering a meaningful share of output, and disclosed gross-margin economics that support the implied price realization. Conversely, a discounted equity raise, convertible financing, delayed construction, or weak utilization at current facilities would confirm that announced capacity is promotional rather than investable.

Key Decisions for Investors

• Do not initiate a directional CBAT long on the announcement. Treat any >20-25% liquidity-driven move without financing, capex, and offtake disclosures as a tactical fade/watch setup rather than fundamental upside.
• Set a 1-3 month CBAT diligence alert for four disclosures: total capex and subsidy contribution, financing instrument, binding customer offtake, and third-party sodium-cell certification. Upgrade only if these establish a path to build without materially dilutive equity issuance.
• For sodium-ion exposure, prefer diversified scale incumbents CATL (300750.SZ) or BYD (1211.HK) where accessible; their procurement scale and established storage channels provide better odds of monetizing adoption than CBAT's pre-construction capacity claim.
• If CBAT rallies materially on momentum, consider a small short only where borrow is available and liquidity permits, with a 1-3 month horizon. Cover on a funded non-dilutive financing plus named offtake; the principal risk is a retail-driven squeeze in a thinly traded micro-cap.